School of Medicine
Showing 91-100 of 105 Results
Arturo Lopez Pineda
Postdoctoral Research Fellow, Genetics
Bio Arturo Lopez Pineda is a biomedical informatician currently receiving postdoctoral training in Population Genomics at the Bustamante Lab at Stanford University. His areas of interest include clinical informatics and translational bioinformatics. Currently, he is working closely with partners from the Mexican Institute of Social Security (IMSS) to strengthen their data science capabilities in order to create a cancer registry using their newly implemented Electronic Health Record (EHR).
Arturo is a Fulbright Science and Technology Scholar, and a member of Mexico's National System of Researchers (SNI). He holds a PhD and MS in Biomedical Informatics from the University of Pittsburgh School of Medicine, and a MS in Intelligent Systems and BS in Computer Science, both from Tecnologico de Monterrey (ITESM).
Arturo has worked closely with students and faculty as Director of the Computer Science Undergraduate Program at ITESM. Also, he has been a research intern at Mexico?s National Institute for Genomic Medicine (INMEGEN), and at the University of Pittsburgh?s Center for Health Informatics for the Underserved, assessing the use of EHRs in Malawi.
Postdoctoral Research Fellow, Pathology
Bio 10.2010 to 07.2015: PhD studies: "Total Synthesis of naturally occuring glycosylated tetramic acids" at the Chair of Organic Chemistry, University of Bayreuth
22.01.2010: diploma in chemistry at the University of Stuttgart
07.2009 to 01.2010:diploma thesis "Synthesis and Biological evaluation of novel alpha-glucosidase inhibitors" at the Oxford Glycobiology Institute, group of Dr. Terry D. Butters (University Oxford Scholarship)
04.2009 to 06.2009: final exams for diploma
02.2008 to 10.2008: research project "De Novo Synthesis of glucosamine" at the ETH Zurich, Departement of Chemistry and Biosciences, group of Prof. Peter H. Seeberger
15.06.2007: intermediate diploma in chemistry
03.2005 to 05.2005: research project "Electrospinning of Diphenylalanine" at the Max-Planck-Institute for Solid State Research, group of Prof. Klaus Kern
10.2004: academic studies of chemistry, diploma
Postdoctoral Research Fellow, Molecular and Cellular Physiology
Bio My research in the Garcia Lab is focused on understanding the molecular basis for Notch receptor-ligand interactions, a critical signaling event for mammalian cell fate determination and the pathogenesis of many cancers. Until recently, we had not been able to ?see? how Notch receptors engage ligands Delta-like and Jagged because their nearly undetectable binding affinity prevents reconstitution of stable complexes for structural studies. To overcome this obstacle, we used in vitro evolution to engineer mutations in Delta-like 4 (DLL4) that enhanced affinity for Notch1 and facilitated co-crystallization of the complex. The Notch1-DLL4 structure revealed an antiparallel, two-site binding interface in which O-linked glycan modifications of Notch1 residues make specific and essential contacts with DLL4. Changes in Notch glycosylation state are known to bias recognition towards certain ligands, and the Notch1-DLL4 structure thus rationalizes a mechanism for glycan-mediated tuning of Notch-ligand selectivity. The elucidation of a direct chemical role for O-glycans in Notch1 ligand engagement demonstrates how, by relying on posttranslational modifications of their ligand binding sites, Notch proteins have linked their functional capacity to developmentally regulated biosynthetic pathways
Gaining structural access to the Notch-ligand interface was a critical first step toward improved therapeutic targeting of the pathway. With this structural information to guide us, we will now be able to design novel ligands with enhanced selectivity and affinity for a number of immunologically focused applications. For example, we are generating (1) receptor-specific ligands that inhibit tumor growth while minimizing off-target toxicity, (2) stromal cell lines that express high-affinity ligands to enhance T-cell maturation in vitro, and (3) bi-specific ligands that activate Notch on desired cell types. In the future, we hope to create a diverse ?toolbox? of engineered ligands for use as diagnostics and therapeutics in a variety of contexts.